Pregabalin is a commonly used drug in neurology, which has the functions of anti-epilepsy, sedation and anti-anxiety. In the animal experimental study, pregabalin has an anticonvulsant effect on all kinds of epileptic animal models, and its activity is 3-10 times higher than that of gabapentin. Clinically, pregabalin is generally used for the following diseases:
1. Improve neuralgia, including peripheral neuralgia caused by diabetic peripheral neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, postoperative toothache, arthritis, etc.
2. It is antiepileptic and is used for the auxiliary treatment of partial seizures.
3. It is anti-anxiety, used for the auxiliary treatment of anxiety and social phobia.
Pregabalin / Lyrica developed by Pfizer is a related compound of gabapentin / Neurontin. In July 2004, pregabalin was approved by the European Union for the management of peripheral neuropathic pain and as an additional therapeutic drug for partial epilepsy. At the end of December 2004, pregabalin was approved in the United States to relieve diabetic peripheral neuropathic pain and postherpetic neuralgia, making it the first drug officially approved in the United States to treat both neuropathic pains. In 2005, it was approved by the FDA for the adjuvant treatment of partial seizures in adult epilepsy patients. In June 2007, the US FDA approved Lyrica for fibromyalgia, which is the first FDA approved drug for fibromyalgia.